Drug Trial Radar · NCT04201561
High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy
Last checked: Nov 20, 2026Latest source record: Jun 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
68
Planned (sponsor's estimate)
Start
Dec 24, 2019
Primary completion
Apr 30, 2023
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Seoul National University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boryung Pharmaceutical Co., Ltd
- First posted
- Dec 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 19 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and efficacy of high dose inorganic selenium in preventing and relieving chemotherapy-induced peripheral neuropathy (CIPN) in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer patients. This study will be conducted as a phase III randomized controlled trial in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer patients who are expected to undergo paclitaxel-carboplatin chemotherapy. A total of 68 patients need to be enrolled in this study. The primary objective of this study is to evaluate the frequency of chemotherapy-induced peripheral neuropathy. The secondary objectives are the evaluation of the severity of peripheral neuropathy and the quality of life to show that selenium is effective in preventing and relieving peripheral neuropathy induced by paclitaxel. Positive results in this study will lead to further studies investigating the effect of selenium on other chemotherapies that can induce peripheral neuropathy.
Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Recurrent Ovarian Carcinoma
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
Interventions
sodium selenite pentahydrateDrug
High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
Normal salineDrug
Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
ChemotherapyDrug
Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of chemotherapy-induced peripheral neuropathy (3m)Time frame: Examined at 3 months after last paclitaxel chemotherapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.